CD274 and head and neck squamous cell carcinoma: Inhibition of the PD-1/PD-L1 axis in HNSCC has resulted in a ~20% response rate and improved overall survival and anti–PD-1 therapy is now approved for frontline treatment of recurrent or metastatic HNSCC (17).